| Delmar Gardens Of Meramec Valley | |
| #1 Arbor Terrace, Fenton, Missouri 63026 | |
| (636) 343-0016 | |
| Name | Delmar Gardens Of Meramec Valley |
|---|---|
| Location | #1 Arbor Terrace, Fenton, Missouri |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 153 |
| Occupancy Rate | 67.45% |
| Medicare ID (CCN) | 265711 |
| Legal Business Name | Delmar Gardens Of Meramec Valley Operating, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1013903525 |
| Organization Name | DELMAR GARDENS OF MERAMEC VALLEY OPERATING, LLC |
| Doing Business As | DELMAR GARDENS OF MERAMEC VALLEY |
| Address | 1 Arbor Ter, Fenton, MO 63026 |
| Phone Number | 636-343-0016 |
News Archive
The U.S. infertility specialty has empirically incorporated greater amounts of human menopausal gonadotropin (hMG) into stimulation protocols, according to a new review article, "Gonadotropins in the Treatment of Infertility" by George T. Koulianos, MD, published in a recent issue of US Obstetrics & Gynecology, supported by an educational grant from Ferring Pharmaceuticals. The article reviews the wealth of clinical evidence supporting this trend, and demonstrates how the use of gonadotropins in the treatment of infertility, especially in assisted reproductive technologies, has significantly improved outcomes.
Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.
A new report by researchers at RTI Health Solutions and parent company RTI International, found that although healthcare databases have allowed for greater access to real world medical data, using databases to evaluate the safety of medical products is complex and requires careful research consideration.
Solvay has re-evaluated the commercial potential of bifeprunox, a Solvay compound in clinical development for the treatment of schizophrenia . Bifeprunox additionally has the potential to be developed in other disorders, i.e. bipolar disorder.
Researchers from Cardiff University have established a link between a genetic mutation and developmental movement impairments in autism.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
The U.S. infertility specialty has empirically incorporated greater amounts of human menopausal gonadotropin (hMG) into stimulation protocols, according to a new review article, "Gonadotropins in the Treatment of Infertility" by George T. Koulianos, MD, published in a recent issue of US Obstetrics & Gynecology, supported by an educational grant from Ferring Pharmaceuticals. The article reviews the wealth of clinical evidence supporting this trend, and demonstrates how the use of gonadotropins in the treatment of infertility, especially in assisted reproductive technologies, has significantly improved outcomes.
Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.
A new report by researchers at RTI Health Solutions and parent company RTI International, found that although healthcare databases have allowed for greater access to real world medical data, using databases to evaluate the safety of medical products is complex and requires careful research consideration.
Solvay has re-evaluated the commercial potential of bifeprunox, a Solvay compound in clinical development for the treatment of schizophrenia . Bifeprunox additionally has the potential to be developed in other disorders, i.e. bipolar disorder.
Researchers from Cardiff University have established a link between a genetic mutation and developmental movement impairments in autism.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 7.26 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 7.59 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 49.29 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.09 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 7.62 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.84 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.26 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 95.26 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 11.38 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 86.47 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.61 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 8.23 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 12.46 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 11.82 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.81 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 88.2 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 91.7 | 82.93 |
News Archive
The U.S. infertility specialty has empirically incorporated greater amounts of human menopausal gonadotropin (hMG) into stimulation protocols, according to a new review article, "Gonadotropins in the Treatment of Infertility" by George T. Koulianos, MD, published in a recent issue of US Obstetrics & Gynecology, supported by an educational grant from Ferring Pharmaceuticals. The article reviews the wealth of clinical evidence supporting this trend, and demonstrates how the use of gonadotropins in the treatment of infertility, especially in assisted reproductive technologies, has significantly improved outcomes.
Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.
A new report by researchers at RTI Health Solutions and parent company RTI International, found that although healthcare databases have allowed for greater access to real world medical data, using databases to evaluate the safety of medical products is complex and requires careful research consideration.
Solvay has re-evaluated the commercial potential of bifeprunox, a Solvay compound in clinical development for the treatment of schizophrenia . Bifeprunox additionally has the potential to be developed in other disorders, i.e. bipolar disorder.
Researchers from Cardiff University have established a link between a genetic mutation and developmental movement impairments in autism.
› Verified 6 days ago
Cori Manor Healthcare & Rehabilitation Center Location: 560 Corisande Hills Road, Fenton, Missouri 63026 Phone: (636) 343-2282 | |
Delmar Gardens Of Meramec Valley Location: #1 Arbor Terrace, Fenton, Missouri 63026 Phone: (636) 343-0016 | |